Sørlandet sykehus Kristiansand
- Address
- lock Available on a paid plan
Sørlandet sykehus Kristiansand
Sørlandet sykehus Kristiansand is a clinical research center engaged in diverse therapeutic investigations spanning pediatric rheumatology and infectious disease management. The center demonstrates expertise in evaluating treatment optimization strategies and antimicrobial stewardship in distinct patient populations.
- Juvenile Idiopathic Arthritis treatment withdrawal strategies and disease remission maintenance
- Antibiotic stewardship in viral respiratory tract infections
- Pediatric and adult immunology and infectious disease therapeutics
The research center's investigations include the MOVE-JIA trial examining methotrexate and TNF inhibitor withdrawal strategies in children with sustained inactive disease, as well as the ATHENIAN study evaluating the safety of antibiotic discontinuation in adults with confirmed viral respiratory infections. These pragmatic trials reflect a commitment to evidence-based practice optimization and reducing unnecessary medication exposure across age groups.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 16 therapeutic areas and 15 of 124 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 115 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 27 by active trials.
- 1Oslo University Hospital HF6active
lock +26 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Oslo University Hospital HF10trials
lock +7 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 112 other sites in Norway
Therapeutic Area Benchmark — Norway
Select a therapeutic area to compare against other sites in Norway.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Norway
Market Share
Country: Norway
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Sørlandet sykehus Kristiansand
lock Showing 1 of 47 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Multicenter Non-Inferiority Trial Comparing Rituximab and Ocrelizumab in Patients with Active Relapsing-Remitting Multiple Sclerosis Aged 18-60 Years | Helse Bergen HF | Phase III | Recruiting | Oct 2020 | — |
IMP list
lock Showing 1 of 124 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Bevacizumab | 4 | Unknown | 2021-02-16 | 2026-04-30 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.